Showing results 1 to 20 of 26
next >
| Issue Date | Title | Author(s) |
| 2011 | A 3-DAY ORAL APREPITANT REGIMEN PROVIDES SUPERIOR PREVENTION OF CINV OVER STANDARD THERAPY IN CHINESE PATIENTS RECEIVING HIGH-DOSE CISPLATIN | Zhang, Li; Cheng, Ying; Zhang, Hong-Yu; Zhou, Caicun; Han, Baohui; Zhang, Yiping; Huang, Cheng; Chang, Jianhua; Song, Xiang Q.; Liang, Jun; Liang, Houjie; Bai, Chunxue; Yu, Shiying; Chen, Jia; Wang, Jie; Pan, Hongming; Carides, Alexandra; Chitkara, Denesh |
| 2018 | Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung | Lu, Shun; Li, Wei; Zhou, Caicun; Hu, Cheng-Ping; Qin, Shukui; Cheng, Gang; Feng, Jifeng; Wang, Jie; Cseh, Agnieszka; Peil, Barbara; Gibson, Neil; Ehrnrooth, Eva; Zhang, Li |
| 2019 | Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors | Wang, Yuetong; Zhang, Jian; Ren, Shengxiang; Sun, Dan; Huang, Hsin-Yi; Wang, Hua; Jin, Yujuan; Li, Fuming; Zheng, Chao; Yang, Liu; Deng, Lei; Jiang, Zhonglin; Jiang, Tao; Han, Xiangkun; Hou, Shenda; Guo, Chenchen; Li, Fei; Gao, Dong; Qin, Jun; Gao, Daming; Chen, Luonan; Lin, Shu-Hai; Wong, Kwok-Kin; Li, Cheng; Hu, Liang; Zhou, Caicun; Ji, Hongbin |
| Feb-2021 | Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial | Fan, Yun; Zhao, Jun; Wang, Qiming; Huang, Dingzhi; Li, Xingya; Chen, Jianhua; Fang, Yong; Duan, Jianchun; Zhou, Caicun; Hu, Yanping; Yang, Haihua; Hu, Yi; Zhou, Jianying; Lin, Xiaoyan; Wang, Lifeng; Wang, Zhijie; Xu, Yanjun; Zhang, Tao; Shi, Wei; Zou, Jianjun; Wang, Jie |
| Aug-2020 | Camrelizumab plus apatinib in extensive-stage small-cell lung cancer (PASSION): A multicenter, two-stage, phase 2 trial | Wang, Jie; Fan, Yun; Zhao, Jun; Wang, Qiming; Huang, Dingzhi; Li, Xingya; Chen, Jianhua; Fang, Yong; Wang, Zhijie; Zhou, Caicun; Hu, Yanping; Yang, Haihua; Hu, Yi; Zhou, Jianying; Lin, Xiaoyan; Wang, Lifeng; Xu, Yanjun; Li, Hanying |
| Mar-2021 | Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial | Zhou, Caicun; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, LiZhu; Feng, Jifeng; Wang, Zhehai; Shu, Yongqian; Shi, Jianhua; Hu, Yi; Wang, QiMing; Cheng, Ying; Wu, Fengying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng; Zhang, Yiping; Pan, Yueyin; Zhao, Jun; Wang, LiPing; Chang, Jianhua; Chen, Qun; Ren, Xiubao; Zhang, Wei; Fan, Yun; He, Zhiyong; Fang, Jian; Gu, Kangsheng; Dong, XiaoRong; Zhang, Tao; Shi, Wei; Zou, Jianjun |
| 2017 | A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel | Wu, Yi-Long; Wang, Chang-Li; Sun, Yan; Liao, Mei-Lin; Guan, Zhong-Zhen; Yang, Zhi-Min; Zhou, Qing-Hua; Lu, Shun; Cheng, Ying; Liu, Xiao-Qing; Zhang, Xu-Chao; Zhou, Caicun; Wang, Jie; Zhou, Qing; Song, Yong; Han, Bao-Hui; Ma, Zhi-Yong; Yang, Fan; Wang, Qun; Chuai, Shao-Kun; Shao, Yang; He, Wei; Zhu, Guanshan; Xiong, Lei; Wang, Jian-Jun; Chen, Ke-Neng; Zhang, Li; Mao, Wei-Min; Ma, Sheng-Lin; Feng, Ji-Feng; Yang, Xue-Ning; Xu, Lin; Chen, Gang; Zhao, Jian; Song, Qi-Bin; Shen-Tu, Yang; Qiao, Gui-Bin; Yu, Ding; Yu, Shi-Ying; Hu, Yi; Chen, Ming; Chen, Go |
| 2018 | Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial | Wang, Zhijie; Cheng, Ying; An, Tongtong; Gao, Hongjun; Wang, Kai; Zhou, Qing; Hu, Yanping; Song, Yong; Ding, Cuimin; Peng, Feng; Liang, Li; Hu, Yi; Huang, Cheng; Zhou, Caicun; Shi, Yuankai; Zhang, Li; Ye, Xin; Zhang, Meizhuo; Chuai, Shaokun; Zhu, Guanshan; Hu, Jin; Wu, Yi-long; Wang, Jie |
| 2011 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study | Zhou, Caicun; Wu, Yi-Long; Chen, Gongyan; Feng, Jifeng; Liu, Xiao-Qing; Wang, Changli; Zhang, Shucai; Wang, Jie; Zhou, Songwen; Ren, Shengxiang; Lu, Shun; Zhang, Li; Hu, Chengping; Hu, Chunhong; Luo, Yi; Chen, Lei; Ye, Ming; Huang, Jianan; Zhi, Xiuyi; Zhang, Yiping; Xiu, Qingyu; Ma, Jun; Zhang, Li; You, Changxuan |
| 20-May-2020 | Establishment of the first international large-scale, genomic screening platform to identify patients with rare oncogene drivers in non-small cell lung cancer (NSCLC) in East Asia. | Matsumoto, Shingo; Zhou, Caicun; Kuo, Chih-Hsi; Yoh, Kiyotaka; Kato, Terufumi; Nishino, Kazumi; Furuya, Naoki; Zhang, Shucai; Lin, Dongmei; Han, Yuchen; Wang, Chin-Chou; Ikeda, Takaya; Zenke, Yoshitaka; Goto, Koichi |
| 2015 | Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma | Cai, Weijing; Lin, Dongmei; Wu, Chunyan; Li, Xuefei; Zhao, Chao; Zheng, Limou; Chuai, Shannon; Fei, Ke; Zhou, Caicun; Hirsch, Fred R. |
| Nov-2022 | Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy | Wu, Fengying; Jiang, Tao; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, Lizhu; Feng, Jifeng; Wang, Zhehai; Shu, Yongqian; Shi, Jianhua; Hu, Yi; Wang, Qiming; Cheng, Ying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng; Zhang, Yiping; Pan, Yueyin; Zhao, Jun; Wang, LiPing; Chang, Jianhua; Chen, Qun; Ren, Xiubao; Zhang, Wei; Fan, Yun; He, Zhiyong; Fang, Jian; Gu, Kangsheng; Dong, Xiaorong; Zhang, Tao; Shi, Wei; Zou, Jianjun; Bai, Xuejuan; Ren, Shengxiang; Zhou, Caicun |
| 2015 | An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer. | He, Jianxing; Shi, Yuankai; Chang, Jianhua; Wang, Mengzhao; Han, Baohui; Liu, Xiaoqing; Chen, Gongyan; Zhou, Caicun; Liu, Jiwei; Pan, Hongming; Huang, Cheng; Zhang, Shucai; Feng, Jifeng; Lin, Xiaoyan; Wang, Jie; Huang, Jianjin; Li, Fang; Qin, Shukui; Wang, Zhehai; Wang, Liwei |
| 2015 | An open-label, randomized, multicenter, phase III study of S-1 and cisplatin versus docetaxel and cisplatin in patients with untreated advanced non-small-cell lung cancer. | He, Jianxing; Shi, Yuankai; Chang, Jianhua; Wang, Mengzhao; Han, Baohui; Liu, Xiaoqing; Chen, Gongyan; Zhou, Caicun; Liu, Jiwei; Pan, Hongming; Huang, Cheng; Zhang, Shucai; Feng, Jifeng; Lin, Xiaoyan; Wang, Jie; Huang, Jianjin; Li, Fang; Qin, Shukui; Wang, Zhehai; Wang, Liwei |
| Jul-2021 | ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC). | Shi, Yuankai; Wu, Lin; Yu, Xinmin; Wang, Yan; Xing, Puyuan; Zhou, Jianying; Wang, Airong; Shi, Jianhua; Hu, Yi; Wang, Ziping; An, Guangyu; Fang, Yong; Sun, Sanyuan; Zhou, Caicun; Wang, Changli; Ye, Feng; Li, Xingya; Wang, Junye; Wang, Mengzhao; Liu, Yunpeng; Zhao, Yanqiu; Feng, Jifeng |
| 2012 | Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCL | Zhou, Caicun; Wu, Yi Long; Liu, Xiaoqing; Wang, Changli; Chen, Gongyan; Feng, Ji Feng; Zhang, Shucai; Wang, Jie; Zhou, Songwen; Ren, Shengxiang; Lu, Shun; Zhang, Li; Hu, Cheng-ping; Luo, Yi; Chen, Lei; Ye, Ming; Huang, Jianan; Zhi, Xiuyi; Zhang, Yiping; Xiu, Qingyu |
| 2016 | Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer | Xu, Naiqing; Fang, Wenfeng; Mu, Libing; Tang, Yanna; Gao, Lei; Ren, Shengxiang; Cao, Dengfeng; Zhou, Lixin; Zhang, Aiqun; Liu, Deruo; Zhou, Caicun; Wong, Kwok-Kin; Yu, Lei; Zhang, Li; Chen, Liang |
| Apr-2021 | A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients withEGFR-mutated,MET-amplified advanced non-small-cell lung cancer | Yang, Jin-Ji; Fang, Jian; Shu, Yong-Qian; Chang, Jian-Hua; Chen, Gong-Yan; He, Jian Xing; Li, Wei; Liu, Xiao-Qing; Yang, Nong; Zhou, Caicun; Huang, Jian An; Frigault, Melanie M.; Hartmaier, Ryan; Ahmed, Ghada F.; Egile, Coumaran; Morgan, Shethah; Verheijen, Remy B.; Mellemgaard, Anders; Yang, Liu; Wu, Yi-Long |
| Jan-2022 | A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naive Patients with EGFRm plus NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China | Tu, Hai-Yan; Feng, Jifeng; Shi, Meiqi; Zhao, Jun; Wang, Yuyan; Chang, Jianhua; Wang, Jialei; Cheng, Ying; Zhu, Jing; Tan, Eng-Huat; Li, Kai; Zhang, Yiping; Lee, Victor; Yang, Cheng-Ta; Su, Wu-Chou; Lam, David Chi-Leung; Srinivasa, B. J.; Rajappa, Senthil; Ho, Ching-Liang; Lam, Kwok Chi; Hu, Yi; Bondarde, Shailesh Arjun; Liu, Xiaoqing; Tian, Yahui; Xue, Zhiyi; Cseh, Agnieszka; Huang, Dennis Chin-Lun; Zhou, Caicun; Wu, Yi-Long |
| 2018 | Prognostic value of PD-L1 expression in combination with CD8(+) TILs density in patients with surgically resected non-small cell lung cancer | Yang, Hui; Shi, Jinpeng; Lin, Dongmei; Li, Xuefei; Zhao, Chao; Wang, Qi; Zhang, Limin; Jiang, Tao; Zhao, Sha; Liu, Xiaozhen; Jia, Yijun; Zhang, Yajun; Cai, Weijing; Zhou, Caicun |
